Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 34 of 34 publications.

Ahn M, Kang JH, Kim S, Kahangarie D, Nagar SP, Davis KL, Jimenez M, Seo M, Jung M, Sandelin M, Cho BC. Treatment (tx) patterns and outcomes in resectable early-stage NSCLC in South Korea: subgroup analysis of a global real-world (rw) study. Poster presented at the ESMO Asian Congress 2023; December 2, 2023. Singapore, China. [abstract] Ann Oncol. 2023; 34(Suppl 4):S1646-53.

Morris MJ, de Bono J, Nagarajah J, Wei XX, Nordquist T, Koshkin VS, Vickers A, Mirante O, Ghouse R, Tagawa S, Fizazi K. Radiographic progression‑free survival correlation with time‑to‑event endpoints: a post hoc analysis of the VISION trial. Poster presented at the 2022 ESMO Annual Congress; September 9, 2022. Paris, France. [abstract] Ann Oncol. 33(supplement 3):S1170-1. doi: 10.1016/j.annonc.2022.07.1506

Li D, Tan A, Hernandez S, Reilly N, Bussberg CJ, Mansfield C. Patient preferences for unresectable hepatocellular carcinoma (HCC) treatments: balancing overall survival and quality of life. Poster presented at the ESMO 24th World Congress on Gastrointestinal Cancer 2022; June 2022. Barcelona, Spain. [abstract] Ann Oncol. 2022 Jun; 33(Suppl 4):s293.

Taylor MH, Leboulleux S, Panaseykin S, Konda B, de La Fouchardiere C, Hughes BGM, Gianoukakis AG, Park YJ, Romanov I, Krzyzanowska MK, Garbinsky D, Sherif B, Pan JJ, Binder TA, Sauter N, Xie R, Brose MS. Health-related quality-of-life (HRQoL) analyses from study 211: a phase 2 study in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) treated with 2 starting doses of lenvatinib (LEN). Poster presented at the 46th Congress of European Society for Medical Oncology (ESMO); September 16, 2021. [abstract] Ann Oncol. 2021; 32(suppl_5):S1205-10. doi: 10.1016/annonc/annonc715

Ali MS, Berencsi K, Marinier K, Deltour N, Perez-Gutthann S, Pedersen L, Rijnbeek P, Lapi F, Simonetti M, Reyes C, Van der Lei J, Sturkenboom M, Prieto-Alhambra D. Comparative cardiovascular safety of strontium ranelate and bisphosphonates: a multi-database study in 5 EU countries by the EU-ADR Alliance. Osteoporos Int. 2020 Dec;31(12):2425-38.

Gilsenan A, Harris D, Reynolds M, McSorley D, Midkiff K, Jackson L, Muldavin B, Kellier-Steele N, Andrews E. Long-term cancer surveillance: results from the Forteo Patient Registry Surveillance Study. Osteoporos Int. 2020 Nov 5;32(4):645-51. doi: 10.1007/s00198-020-05718-0

Berencsi K, Sami A, Ali MS, Marinier K, Deltour N, Perez-Gutthann S, Pedersen L, Rijnbeek P, Van der Lei J, Lapi F, Simonetti M, Reyes C, Sturkenboom MCJM, Prieto-Alhambra D. Impact of risk minimisation measures on the use of strontium ranelate in Europe: a multi-national cohort study in 5 EU countries by the EU-ADR Alliance. Osteoporos Int. 2020 Apr;31(4):721-55. doi: 10.1007/s00198-020-05314-2

Haque R, Shi JM, Telford C, Avila C, Alvarado M, Tiller GE, Dalvi T, Gutierrez L, Tyczynski J, Kaye JA. Survival outcomes in BRCA1 or BRCA2 mutation carriers and the influence of triple-negative breast cancer subtype. Perm J. 2018 Oct 11;22:17-197. doi: 10.7812/TPP/17-197

Gilsenan A, Harding A, Kellier-Steele N, Harris D, Midkiff K, Andrews E. The Forteo patient registry linkage to multiple state cancer registries: study design and results from the first 8 years. Osteoporos Int. 2018 Oct;29(10):2335-43. doi: 10.1007/s00198-018-4604-8

Martin S, Pawer V, Harris N, Gnanasakthy A. Symptoms of gastric cancer from a patient perspective. Poster presented at the ESMO 19th World Congress on Gastrointestinal Cancer; June 28, 2017. Barcelona, Spain. [abstract] Ann Oncol. 2017 Jun; 28(Suppl 3).

Bover I, Colombo N, Korach J, Davis KL, Kaye JK, Lewis IRR, Callejo A, Gasco A. Treatment patterns and BRCA testing practice in platinum-sensitive recurrent serous ovarian cancer: a Spanish medical record review. Poster presented at the 2016 European Society for Medical Oncology Congress; October 7, 2016. Copenhagen, Denmark. [abstract] Ann Oncol. 2016 Oct 11; 27(suppl_6). doi: 10.1093/annonc/mdw374.24

Hoffman V, Xue F, Gardstein B, Skerry K, Critchlow CW, Enger C. Assessment of off-label use of denosumab 60 mg injection during the early postmarketing period using health insurance claims data. Osteoporos Int. 2016 Apr;27(4):1653-8. doi: 10.1007/s00198-015-3402-9

Gold R, Esterberg E, Hollombe C, Arkind J, Vakarcs PA, Tran H, Burdick T, Devoe JE, Horberg MA. Low back imaging when not indicated: a descriptive cross-system analysis. Perm J. 2016;20(2):25-33. doi: 10.7812/TPP/15-08

Casulo C, Day B, Dawson KL, Zhou X, Flowers CR, Farber CM, Hainsworth JD, Cerhan JR, Link BK, Zelenetz AD, Friedberg JW. Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study. Ann Oncol. 2015 Nov;26(11):2311-7. doi: 10.1093/annonc/mdv375

Fernandez-Martos C, Garcia-Albeniz X, Pericay C, Maurel J, Aparicio J, Montagut C, Safont MJ, Salud A, Vera R, Massuti B, Escudero P, Alonso V, Bosch C, Martin M, Minsky BD. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol. 2015 Aug;26(8):1722-8. doi: 10.1093/annonc/mdv223

Andrews EB, Gilsenan AW, Midkiff KD, Harris DH. Comments on Bang et al.: the impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporos Int. 2015 May;26(5):1663-4. doi: 10.1007/s00198-014-3003-z

Overman RA, Gourlay ML, Deal CL, Farley JF, Brookhart MA, Layton JB. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis. Osteoporos Int. 2015 May;26(5):1515-24. doi: 10.1007/s00198-014-3022-9

Danson S, Andreas S, Chouaid C, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue M, Barth J, Price M, Wolowacz SE, Kaye JA, Kontoudis I. LuCaBIS: a burden of illness study in patients with stage IB-IIIA non-small cell lung cancer in France, Germany and the UK. Poster presented at ESMO (European Society for Medical Oncology) 2014 Congress; September 29, 2014. Madrid, Spain. [abstract] Ann Oncol. 2014 Sep 1; 25(Suppl 4):iv415-6. doi: 10.1093/annonc/mdu347

Mohr P, Harries M, Grange F, Ehness R, Benajmin L, Siakpere O, McLeod LD, Wolowacz SE, Kaye JA, Kontoudis I. Treatment patterns and disease burden of stage IIIB/IIIC melanoma in France, Germany and the UK. Poster presented at the ESMO 2014 Congress; September 28, 2014. Madrid, Spain. [abstract] Ann Oncol. 2014 Sep 1; 25(suppl 4):iv389. doi: 10.1093/annonc/mdu344.40

Nooka AK, Nabhan C, Zhou X, Taylor MD, Byrtek M, Miller TP, Friedberg JW, Zelenetz AD, Link BK, Cerhan JR, Sinha R, Shenoy PJ, Levy D, Dawson K, Hirata JH, Flowers CR. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol. 2013 Feb 1;24(2):441-8.

Zafar SY, Grothey A, Bekaii-Saab T, Bendell J, Sherrill B, Bennett L, Mun Y, Sersch M, Dalal D, Hurwitz HI. Survival among metastatic colorectal cancer (MCRC) patients treated in a randomized controlled trial (RCT) vs an observational cohort study (OCS). Poster presented at the 37th Annual Congress of the European Society for Medical Oncology; September 1, 2012. [abstract] Ann Oncol. 2012 Sep 1; 23(Suppl. 9):191.

Burris H, Beck JT, Rugo H, Baselga J, Lebrun F, Taran T, Bennett L, Ricci J, Sahmoud T, Hortobagyi GN. Health-related quality of life (QoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane monotherapy. Poster presented at the ESMO 2012 Conference; September 2012. [abstract] Ann Oncol. 2012 Sep; 23(Suppl. 9):121-2.

Armbruster B, Lucas AM. Effectiveness of a no-sex or safe-sex month in reducing HIV transmission. Bull World Health Organ. 2012 Jul;90(7):477-556. doi: 10.2471/BLT.11.088641

McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, Adekunle F, Roberts D. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int. 2011 Jul 1;22(7):2083-98.

Peeters M, Bennett L, Zhao ZY, Barber B, Zhou X, Zhang J, Xu F, Wiezorek J, Douillard JY. Panitumumab (PMAB) in combination with chemotherapy (CT) versus CT alone: health-related quality of life (HRQOL) in patients (PTS) with wild-type (WT) KRAS metastatic colorectal cancer (MCRC). Poster presented at the European Society for Medical Oncology 13th World Congress on Gastrointestinal Cancers; June 2011. Barcelona, Spain. [abstract] Ann Oncol. 2011 Jun 1; 22(Suppl. 5):v24.

Chirila C, Odom D, Devercelli G, Khan S, Sherif B, Kaye J, Molnar I, Sherrill B. Meta-analysis of the validity of progression-free survival as a surrogate endpoint for overall survival in metastatic colorectal cancer trials. Poster presented at the 35th European Society for Medical Oncology Congress; October 12, 2010. [abstract] Ann Oncol. 2010 Oct; 21(suppl 8):623P.

Tosteson AN, Do TP, Wade SW, Anthony MS, Downs RW. Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US. Osteoporos Int. 2010 Oct;21(10):1769-80. doi: 10.1007/s00198-009-1133-5

Pattanayak SK, Poulos C, Yang JC, Patil S. How valuable are environmental health interventions? Evaluation of water and sanitation programmes in India. Bull World Health Organ. 2010 Jul 1;88(7):535-42.

Gutierrez L, Roskell N, Rycroft C, Castellsague J, Beard S, Abeysinghe S, Shannon P, Robbins S, Gitlin M. Economic and clinical burden of non-vertebral non-hip (Nvnh), vertebral and multiple fractures in postmenopausal women in the United Kingdom. Poster presented at IOF World Congress on Osteoporosis & 10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; May 2010. Florence, Italy. [abstract] Osteoporos Int. 2010 May 1; 21(Suppl. 1):S96.

Castellsague J, Roskell N, Gutierrez L, Beard S, Rycroft C, Abeysinghe S, Shannon P, Robbins S, Gitlin M. Economic and clinical burden of hip fractures in postmenopausal women in the United Kingdom (UK). Poster presented at the IOF World Congress on Osteoporosis & 10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; May 2010. Florence, Italy. [abstract] Osteoporos Int. 2010 May 1; 21(Suppl. 1):S95.

Pattanayak SK, Yang JC, Dickinson KL, Poulos C, Patil SR, Mallick RK, Blitstein JL, Praharaj P. Shame or subsidy revisited: social mobilization for sanitation in Orissa, India. Bull World Health Organ. 2009 Aug 1;87(8):580-7.

Barrett-Connor E, Ensrud K, Tosteson AN, Varon SF, Anthony M, Daizadeh N, Wade S. Design of the POSSIBLE US trade mark study: postmenopausal women's compliance and persistence with osteoporosis medications. Osteoporos Int. 2009 Mar;20(3):463-72. doi: 10.1007/s00198-008-0674-3

Richards DA, Boehm KA, Waterhouse DM, Wagener DJ, Krishnamurthi SS, Rosemurgy A, Grove W, Macdonald K, Gulyas S, Clark MJ, Dasse KD. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann Oncol. 2006 Jul 1;17:1096-102.

Clarkson TB, Cline JM, Williams JK, Anthony MS. Gonadal hormone substitutes: effects on the cardiovascular system. Osteoporos Int. 1997;7(Suppl 1):543-51.